| |
 |
Spring
Creek Capital Corporation (OTCBB: SCRK )
|
 |
Dear StockUpTicks Reader:
When companies join forces to solve major problems and open doors to
vast and largely untapped markets, the world clearly takes notice. But
when such solutions hold the potential of providing real and immediate
relief to millions of people suffering with chronic diseases, the deal
rises to a more exalted level. An after-market announcement yesterday by Spring
Creek Capital Corp. (OTCBB: SCRK) appears to detail such a deal.
Spring Creek Capital Corp. announced that it had signed a strategic
licensing agreement for an innovative, patented oral spray drug delivery
system via the inner lining of the cheek. According to the release,
it uses a pain free, needle free, and inhalation free delivery system,
that can provide better stability and may reduce the side effects seen
with certain nasal delivery and inhalation methods.
The announcement also notes that the current market applications for
oral spray technology include delivery of insulin for diabetes, a $10.9
billion market in the U.S., and the delivery of calcitonin for osteoporosis,
with worldwide sales in excess of $1 billion.
As an example, for Insulin users, this manner of delivery would eliminate
the need for shots with invasive needles while avoiding the long-term lung
damage observed with other aerosol products that target the lungs for insulin
absorption, according to the news release.
About Spring Creek Capital Corp.
Spring Creek Capital Corp. is a healthcare solutions company whose
business plan is to distribute cutting edge solutions for the medical,
pharmaceutical and healthcare markets to resellers and consumers worldwide.
Spring Creek actively pursues emerging opportunities in the healthcare
industry by selecting young start-up and micro-cap companies with innovative
concepts and launching these products and services utilizing the marketing
distribution network of Spring Creek’s principal subsidiary, Stratis Healthcare
Inc. Through Stratis, Spring Creek will distribute the products of its
portfolio companies either directly to consumers, through distributors
or through multi-channel resources.
View an Investor Fact Sheet on Spring Creek Capital
Corp. HERE
<<<Sapcer>>>
|
Latest NEWS from
Spring Creek Capital Corp. |
|
<<<Spacer>>>
Press Release Source:
Spring Creek Capital Corp.
On Monday May 3,
2010, 4:35 pm EDT
Spring Creek Capital Corp. Signs
Strategic Licensing Agreement
for Patented Oral Drug Delivery
System
Innovative Oral Spray
Technology Is a Patented Process; Administers Medicine Using a Pain Free,
Needle Free, and
Inhalation Free Delivery Method
NEW YORK--(BUSINESS
WIRE)--Spring Creek Capital Corporation (OTCBB: SCRK - News), a healthcare
solutions company whose business plan is distributing cutting edge solutions
for the medical, pharmaceutical and healthcare markets, today announced
that it has signed a strategic licensing agreement for an innovative, patented
oral spray drug delivery system via the inner lining of the cheek.
The licensing agreement
between Spring Creek Capital Corp and McCoy Enterprise, LLC/Vectoris Pharma
LLC, gives Spring Creek the exclusive rights to produce, market, distribute
and sell products based on an innovative method of delivering medicine
via the mouth, more specifically the inner lining of the cheek, known medically
as the buccal mucosa. This patented oral spray process compares favorably
with the foremost technologies in nasal inhalation and injection, and has
the advantage of being socially non intrusive and convenient. Utilizing
this pain free, needle free, and inhalation free delivery system, it can
provide better stability and may reduce the side effects seen with certain
nasal delivery and inhalation methods.
"We are excited to announce
this new licensing agreement, which brings a patented process and an innovative
drug delivery method to Spring Creek’s portfolio," said Kelly T. Hickel,
Chairman and CEO of Spring Creek Capital. “We will utilize this oral drug
delivery system to improve the administration of drugs including chemical
entities, proteins, and peptides without the use of more invasive forms
of drug delivery systems such as needles.”
With the potential to
alleviate a largely untapped market, this oral delivery system was developed
by McCoy Enterprise, LLC, a provider of manufacturing services to medical
device and pharmaceutical manufacturing industries in the United States
and internationally. The company was founded by industry veteran Randall
E. McCoy, who has more than 20 years of experience in scientific research
and development and has helped over 225 foreign and domestic companies
introduce their drug and medical device products into the US and world
market.
Mr. McCoy commented,
“In the case of diabetes patients, by utilizing this patented buccal technology,
patients would be able to receive a spray of their own prescribed insulin
in the cheek rather than by a needle or being inhaled into the lungs. This
manner of delivery does not require insulin shots via invasive needles
and avoids the potential long-term lung damage as with other aerosol products
that target the lungs for insulin absorption.”
Current market applications
for this oral spray technology include delivery of insulin for diabetes,
a $10.9 billion market in the United States, and the delivery of calcitonin
for osteoporosis, with worldwide sales in excess of $1 billion.
Spring Creek Capital’s
corporate initiatives have evolved around the concept of selecting young
companies with innovative concepts and launching these products and services
utilizing its expertise. Management believes this innovative oral spray
drug delivery system will help Spring Creek in its pursuit of building
a portfolio of emerging opportunities and innovative concepts in the healthcare
and pharmaceutical industry.
About Spring Creek
Capital Corp.
Spring Creek Capital
Corp. is a healthcare solutions company whose business plan is to distribute
cutting edge solutions for the medical, pharmaceutical and healthcare markets
to resellers and consumers worldwide. Spring Creek actively pursues emerging
opportunities in the healthcare industry by selecting young start-up and
micro-cap companies with innovative concepts and launching these products
and services utilizing the marketing distribution network of Spring Creek’s
principal subsidiary, Stratis Healthcare Inc. Through Stratis, Spring Creek
will distribute the products of its portfolio companies either directly
to consumers, through distributors or through multi-channel resources.
Forward-Looking Statements
This press release may
contain forward-looking statements within the meaning of Section 27A of
the Securities Act of 1933, as amended, and Section 21E of the Securities
Exchange Act of 1934, as amended. Investors are cautioned that these forward-looking
statements involve uncertainties and risks that could cause actual performance
and results of operations to differ materially from those anticipated.
These risks and uncertainties include issues related to the ability to:
obtain sufficient funding to continue operations, maintain adequate cash
flow, profitably exploit new ventures, as well as other factors set forth
in Spring Creek Capital's most recently filed Form 10-K and Form 10-Q reports.
The forward-looking statements contained herein represent the Company's
judgment as of the date of this release and it cautions readers not to
place undue reliance on such statements. Spring Creek Capital assumes no
obligation to update the statements contained in this release.
Company Contact:
Spring Creek Capital
Corp.
Kelly T. Hickel, Chairman
and CEO
646-896-3050
kthickel@springcreekcapital.net
Financial Communications
Contact:
Trilogy Capital Partners
Darren Minton, Executive
Vice President
Toll-free: 800-592-6067
info@trilogy-capital.com
<<<Spacer>>>
|
Financial Highlights |
|
<<<Spacer>>>
Symbol: SCRK
Exchange: OTCBB
Recent Price: $0.55
52wk Range: 0.55 - 1.05
Shares Outstanding: 34,230,000 (as
of April 15, 2010)
Market Cap (approx): $18.55M (as
of May 03, 2010)
Average 3-Month Volume: 20,000 (as
of May 03, 2010)
View SCRK Filings with the SEC at this LINK
<<<Spacer>>>
|
Company Contact |
|
Spring Creek Capital Corp.
1365 N. Courtenay Parkway, Suite A
Merritt Island, FL 32953
Phone: 321-452-9091
*** The Bull is Running. ***
There
may never be a better time to feature YOUR company
to
over 1 MILLION investors
To learn
more about our programs email us directly at info@stockupticks.com
Market Pathways
17595 Harvard Ave., Suite
C519 Irvine, CA 92614
949-955-0107
Stockupticks
Safe Harbor Statement: Statements contained in this document,
including those pertaining to estimates and related plans, potential mergers
and acquisitions, estimates, growth, establishing new markets, expansion
into new markets and related plans other than statements of historical
fact, are forward-looking statements subject to a number of uncertainties
that could cause actual results to differ materially from statements made.
StockUpTicks.com is a property of Market Pathways Financial Relations Incorporated
(MP). MP provides no assurance as to the subject company's plans
or ability to effect any planned and/or proposed actions. MP has no first-hand
knowledge of management and therefore cannot comment on its capabilities,
intent, resources, nor experience and makes no attempt to do so. Statistical
information, dollar amounts, and market size data was provided by the subject
company and related sources believed by MP to be reliable, but MP provides
no assurance, and none is given, as to the accuracy and completeness of
this information.
Disclaimer: StockUpTicks.com is a property of Market Pathways Financial Relations Incorporated
(MP). The information, opinions and analysis contained herein are
based on sources believed to be reliable but no representation, expressed
or implied, is made as to its accuracy, completeness or correctness. Past
performance is no guarantee of future results. This report is a paid advertisement
and is for information purposes only and should not be used as the basis
for any investment decision. MP has been paid
Five Thousand Five Hundred dollars by Trilogy Capital Partners for preparation
and distribution of this report and other advertising services. This
constitutes a conflict of interest as to MP’s ability to remain objective
in its communication regarding the subject company. Write or call
MP for detailed disclosure as required by Rule 17b of the Securities Act
of 1933/1934. MP is not an investment advisor and this report is
not investment advice. This information is neither a solicitation to buy
nor an offer to sell securities but is a paid advertisement. Information
contained herein contains forward-looking statements and is subject to
significant risks and uncertainties, which will affect the results.
The opinions contained herein reflect our current judgment and are subject
to change without notice. MP and/or its affiliates, associates and employees
from time to time may have either a long or short position in securities
mentioned. Information contained herein may not be reproduced in
whole or in part without the express written consent of Market Pathways
Financial Relations Incorporated.
|
|
